Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma.

Glassia is indicated for patients suffering from lung disease called emphysema, due to a genetic deficiency in the AAT protein.

Takeda holds the license to manufacture and distribute Glassia in the United States, Canada, Australia, and New Zealand, following a completed technology transfer from Kamada.

The company cooperates with the Israeli Ministry of Health, in the framework of which it established a GMP standard for the production of serum against snake venom.

[8] The company has a strategic agreement with Kedrion Pharmaceuticals for the development and marketing of the KamRab rabies immunoglobulin in the United States.